RAPH
Raphael Pharmaceutical Inc.Company Information
- Company Name
- Raphael Pharmaceutical Inc.
- CIK
- CIK0001415397
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- RAPH: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2833
- SIC Description
- Medicinal Chemicals & Botanical Products
- Ticker
- RAPH
SEC filing data through
Insider Sentiment
- Last purchase
- 2009-12-17
- Last sale
- —
- Shares purchased (TTM)
- 1,990,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- —
- Institutional shares owned
- —
- Shares outstanding
- —
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 0.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related Party | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | - | - | ||||||
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Current | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finite Lived Intangible Assets Net | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | ||||||
| Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Other Accrued Liabilities Current | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Short Term Borrowings | - | - | - | - | - | - | 0 | - | - | - | - | - | ||||||
| Notes Payable Current | - | - | - | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Liabilities Current | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity Note Subscriptions Receivable | - | - | - | - | - | - | - | - | - | - | -0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 7 | 7 | ||||||
| Retained Earnings Accumulated Deficit | -11 | -10 | -10 | -10 | -10 | -9 | -9 | -8 | -8 | -8 | -7 | -7 | ||||||
| Stockholders Equity | -2 | -2 | -1 | -1 | -1 | -1 | -1 | -1 | -0 | -0 | 0 | -0 | ||||||
| Liabilities And Stockholders Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 50 | 50 | 21 | 50 | 21 | 21 | 21 | 50 | 50 | 21 | 21 | 21 | ||||||
| Common Stock Shares Issued | 20 | 20 | 20 | 20 | 20 | 20 | 19 | 19 | 19 | 19 | 19 | 18 | ||||||
| Shares Outstanding | 20 | 20 | 20 | 20 | 20 | 20 | 19 | 19 | 19 | 19 | 19 | 18 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialRaphael Pharmaceutical Inc. (RAPH) — SEC Financial Statements & Analysis
Raphael Pharmaceutical Inc. (RAPH) is a medicinal chemicals & botanical products company, incorporated in NV. Raphael Pharmaceutical Inc. trades on OTC as: RAPH. Raphael Pharmaceutical Inc. (RAPH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Raphael Pharmaceutical Inc. carries a market cap of $28.25M, a P/E ratio of 28.82x, a P/B ratio of -14.99x, an enterprise value of $28.25M, and an EV/EBITDA multiple of 30.44x. On profitability, it posts a Return on Equity (ROE) of -66.83% and a Return on Assets (ROA) of 5297.30%. Per share, it reports EPS of $0.05, diluted EPS of $0.05, free cash flow per share of $-0.00, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -33.42% year-over-year and EPS growth of -35.24% year-over-year. On the balance sheet, it maintains a current ratio of 0.00x, a quick ratio of 0.00x, working capital of $-1.89M, a debt-to-equity ratio of -1.00x, a debt ratio of 270.29, an interest coverage ratio of 309.00x, free cash flow of $-15.00K (TTM), and net debt of $-1.00K. Figures sourced from SEC EDGAR.
- Market Cap
- $28.25M
- P/E TTM
- 28.82x
- EPS TTM
- $0.05
- P/B TTM
- -14.99x
- ROE TTM
- -66.83%
- ROA TTM
- 5297.30%
- Debt To Equity
- -1.00x
- Free Cash Flow TTM
- $-15.00K
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Raphael Pharmaceutical Inc. in?
Raphael Pharmaceutical Inc. (RAPH) operates in the Medicinal Chemicals & Botanical Products industry.
What exchange does RAPH trade on?
Raphael Pharmaceutical Inc. (RAPH) trades on the OTC.
Where is Raphael Pharmaceutical Inc. incorporated?
Raphael Pharmaceutical Inc. is incorporated in NV.
When was Raphael Pharmaceutical Inc. (RAPH)'s most recent SEC filing?
Raphael Pharmaceutical Inc. (RAPH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is RAPH's market cap?
Raphael Pharmaceutical Inc. (RAPH) has a market capitalization of $28.25M as of 2026-06-30.
What is RAPH's P/E ratio?
Raphael Pharmaceutical Inc. (RAPH)'s trailing twelve month P/E ratio is 28.82x as of 2026-06-30.
What is RAPH's EPS (earnings per share)?
Raphael Pharmaceutical Inc. (RAPH)'s trailing twelve month EPS is $0.05 as of 2026-06-30.
What is RAPH's ROE (return on equity)?
Raphael Pharmaceutical Inc. (RAPH)'s trailing twelve month Return on Equity (ROE) is -66.83% as of 2026-06-30.
What is RAPH's ROA (return on assets)?
Raphael Pharmaceutical Inc. (RAPH)'s trailing twelve month Return on Assets (ROA) is 5297.30% as of 2026-06-30.
What is RAPH's EV/EBITDA?
Raphael Pharmaceutical Inc. (RAPH)'s trailing twelve month EV/EBITDA is 30.44x as of 2026-06-30.